Can Melatonin Cause Raised Liver Enzymes?
Melatonin generally does NOT cause elevated liver enzymes at typical doses (≤10 mg/day) and is considered safe with minimal hepatotoxic risk, though rare cases of transaminase elevation have been reported, particularly with very high doses (≥300 mg/day) in polymedicated patients.
Evidence from Clinical Guidelines
The most relevant guideline evidence comes from the American Academy of Sleep Medicine's 2015 clinical practice guideline 1, which comprehensively reviewed melatonin's safety profile. This guideline states that melatonin is "associated with a lack of reported serious adverse effects" and that short-term use of ≤10 mg/daily appears safe in healthy adults. Notably, liver enzyme elevation is not listed among the commonly reported adverse effects (which include headaches, somnolence, hypotension, hypertension, gastrointestinal upset, and exacerbation of alopecia areata).
A 2010 guideline on REM sleep behavior disorder 2 reported only one case among 71 patients where clonazepam (not melatonin) caused "transient and reversible increase in liver enzyme," further supporting melatonin's favorable hepatic safety profile at therapeutic doses.
Research Evidence: The Dose-Dependent Picture
The research literature reveals a nuanced, dose-dependent relationship:
Standard Doses (≤10 mg/day): Hepatoprotective Effects
Multiple studies demonstrate that melatonin at standard doses actually improves liver enzymes rather than elevating them:
- A 2017 study 3 showed melatonin (2×5 mg daily) significantly decreased AST, ALT, and GGT levels in patients taking statins over 6 months
- A 2012 study 4 in NASH patients found melatonin (2×5 mg daily) reduced ALT by 32-43%, AST by 33-45%, and GGT by 38-52% over 24 weeks
- A 2020 meta-analysis 5 confirmed melatonin supplementation significantly improved AST, ALP, and GGT in NAFLD patients
- Animal studies 6, 7, 8 consistently show hepatoprotective effects with reduced liver damage markers
Very High Doses (≥300 mg/day): Potential Risk in Specific Populations
The critical safety concern emerges from a 2026 study 9 that was prematurely halted due to hepatotoxicity. This trial used 300 mg/day of melatonin—30-60 times higher than typical doses—in multiple sclerosis patients on ocrelizumab. Three of four patients developed grade 1-2 hypertransaminasemia, which resolved after discontinuation.
Key finding: All affected patients were women taking multiple medications metabolized through shared hepatic CYP450 pathways with melatonin (acetaminophen, metamizole, omeprazole, ibuprofen, NSAIDs). The single male patient not taking such medications experienced no liver-related adverse events during 14 months of treatment.
Clinical Algorithm for Safe Use
For typical doses (3-10 mg/day):
- No routine liver monitoring required
- Melatonin is safe and may actually improve liver enzymes
- Consider melatonin as hepatoprotective in patients with NAFLD/NASH
For high doses (>10 mg/day) or polymedicated patients:
- Assess concomitant medications metabolized via CYP450 pathways (particularly CYP1A2, CYP2C19)
- Common interacting drugs: acetaminophen, NSAIDs, PPIs, certain statins
- Consider baseline and periodic liver function monitoring if multiple CYP450-metabolized drugs are present
- Avoid very high doses (>100 mg/day) in polymedicated patients
If transaminase elevation occurs:
- Discontinue melatonin temporarily
- Elevations are typically transient and reversible 9
- Re-challenge at lower dose may be considered after normalization
Important Caveats
The hepatotoxicity risk appears related to pharmacokinetic drug-drug interactions causing CYP450 pathway saturation rather than direct melatonin hepatotoxicity 9. This is fundamentally different from drugs like lomitapide or mipomersen 10, 11 that carry black box warnings for hepatotoxicity and require REMS programs.
Melatonin's hepatic safety profile at standard doses remains excellent, with the preponderance of evidence showing hepatoprotective rather than hepatotoxic effects 5, 3, 4.